This program aims to assess the therapeutic potential of genetically targeted T-cells in the treatment of leukemia and lymphoma. We recently demonstrated that human peripheral blood T-cells can be genetically redirected to recognize the CD19 antigen and eradicate established, systemic human B-cell tumors borne by immune deficient mice, demonstrating for the first time that genetically modified human T-cells can induce durable remissions in an in-vivo setting. As the final aim of this project, we plan to assess this therapeutic strategy in patients with relapsed B-cell malignancies.

< Return to list of ACGT Fellows